Eli Lilly Tops $1T as Novo Nordisk Reports Wednesday

Eli Lilly's market value sits above $1 trillion on Zepbound and Mounjaro sales and a raised outlook, as Novo Nordisk reports Wednesday under obesity price pressure.

Lead

What Did Eli Lilly Report?

Lilly reported revenue growth of 39% to $24.4 billion, driven almost entirely by its tirzepatide franchise. Mounjaro sales climbed 65% to $10.7 billion and Zepbound rose 49% to $5.4 billion, a combined $16.1 billion in a single quarter.

Adjusted earnings came in at $7.48 a share against $6.26 expected. Volume rose 53% worldwide, while realized prices fell 15%, a reminder that growth is now being bought partly with lower net pricing. In the U.S., volume rose 41% and prices fell 7%.

The full-year revenue range moved to $91-92 billion from $85-87 billion. Adjusted earnings guidance was trimmed to $35-36 a share from $35.50-36.50, because $4.57 a share of acquired research charges from deals outweighed a $4.07 improvement in underlying performance.

Why Did Lilly Cross $1 Trillion?

Lilly crossed $1 trillion because obesity and diabetes demand has outpaced every earlier forecast for the drug class, and the company holds the largest share of it. Lilly's U.S. share of the incretin market stands at about 63%, versus about 37% for Novo, and its international share is about 58%.

Medicare coverage of obesity care under a pilot program began in July, widening the pool of eligible patients. The chief executive has said only 3% to 10% of eligible patients currently receive obesity treatment. The oral drug Foundayo posted $184 million in sales, below the $229 million forecast, though prescriptions doubled from the prior quarter.

Lilly's weight now shapes the profile of broad indexes and any healthcare etf that tracks the sector, which magnifies its moves on earnings days.

Why Is Novo Nordisk Under Pressure?

Novo Nordisk is under pressure because it is losing share to Lilly while U.S. prices for obesity drugs fall. Its shares are down nearly 45% this year and trade near $38.67, giving it a market value of about $172 billion. In February the company warned of a 5% to 13% decline in sales for 2026.

Self-pay pricing for the new Wegovy pill ranges from $149 to $299 a month by dose, well below the list prices that built the franchise. Ozempic sales are expected to fall sharply as that mix shifts.

What Should Be Watched in Novo Nordisk's Results?

The key figures in Novo's report are Wegovy pill revenue, obesity care growth and any change to the 2026 outlook. Consensus compiled by the company calls for third-quarter revenue of about DKK 73.8 billion, down from DKK 75.0 billion a year earlier, and earnings of DKK 4.62 a share.

Wegovy pill sales are expected near DKK 4.5 billion to 4.6 billion, with some forecasts as high as DKK 5.3 billion. Obesity care revenue is projected to grow more than 18%, even as Ozempic declines. A pill result above consensus would support the argument that Novo's oral product can slow the loss of share; a miss would reinforce Lilly's lead.

Strategic Context

The two reports illustrate a market where volume is expanding quickly and price per patient is contracting. Lilly has shown it can absorb a 15% decline in realized prices and still raise guidance. Novo has less margin for that trade, with flat to declining revenue and a smaller base of new-product sales.

Outlook

Lilly enters the final two months of 2026 with raised guidance, a valuation above $1 trillion and the dominant position in tirzepatide. Wednesday's Novo results will show whether the Wegovy pill is arresting its decline or whether price cuts are outrunning volume gains. For both companies, the next test is whether expanded Medicare access and oral launches can sustain growth as net prices keep falling.